At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 139 enrolled
Drug / intervention
Cetuximab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Pre-operative Chemoradiotherapy With or Without Cetuximab (ERBITUX(R)) in Locally-advanced Adenocarcinoma of the Rectum
In Brief
A Phase 2 clinical trial evaluating Cetuximab, 5-fluorouracil, and 1 other intervention for Rectal Cancer. Completed, enrolled 139 participants across 41 sites.
Detailed Summary
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Eli Lilly and Company
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedSep 2007
Primary CompletionJan 2015
TodayJul 2026
First PostedSep 10, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 18.8 years ago
Interventions
Cetuximabdrug
5-fluorouracildrug
Pelvic irradiationradiation